BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising ...

Core Insights - Bristol Myers Squibb's growth portfolio performed strongly in Q3 2025, offsetting declines in legacy drug sales [1][8] - The growth portfolio includes key drugs such as Opdivo, Reblozyl, and Breyanzi, contributing significantly to revenue [1][4] Growth Portfolio Performance - Opdivo remains the top revenue generator, with strong sales driven by its launch in MSI-high colorectal cancer and growth in first-line non-small cell lung cancer in the U.S. [2] - Opdivo Qvantig's approval for subcutaneous use has enhanced the immuno-oncology portfolio, with projected global sales growth in the high single-digit to low double-digit range [3] - Reblozyl is annualizing over $2 billion in sales, driven by demand in various treatment settings [4] - Breyanzi sales have surpassed $1 billion, reflecting strong growth in large B-cell lymphoma [4] - Camzyos sales are increasing due to robust demand, and Cobenfy has shown encouraging initial uptake with $105 million in sales year to date [5] Competitive Landscape - The immuno-oncology market is competitive, with Merck's Keytruda dominating and accounting for around 50% of Merck's pharmaceutical sales [6] - Pfizer is also a significant player in oncology, with a diverse product portfolio including antibody-drug conjugates and biosimilars [7] Financial Performance and Valuation - Bristol Myers' shares have declined by 13.2% year to date, contrasting with the industry's growth of 15.9% [10] - The company is trading at a price/earnings ratio of 8.07x forward earnings, lower than its historical mean and the large-cap pharma industry's average of 16.42x [12] - The Zacks Consensus Estimate for 2025 earnings per share has remained unchanged, while estimates for 2026 have decreased [13]

Core Insights - Bristol Myers Squibb (BMY) has seen a 7.2% increase in stock price over the past month, outperforming the industry growth of 3.8% and the S&P 500 Index [1][2][8] - The company's strong performance is attributed to better-than-expected Q3 results driven by increased demand for key drugs such as Opdivo, Breyanzi, Reblozyl, and Camzyos, leading to an upward revision in revenue guidance [3][8] - Despite recent gains, BMY's year-to-date stock performance has been disappointing, with a decline from a 52-week high of $63.33 in March to a low of $42.52 in late October [4] Financial Performance - BMY's Growth Portfolio, which includes drugs like Opdivo and Reblozyl, reported an 18% year-over-year sales increase, totaling $6.9 billion [5] - Opdivo sales in the U.S. are driven by strong launches in specific cancer indications, while global sales are expected to grow in the high single-digit to low double-digit range [6][8] - The thalassemia drug Reblozyl has annualized sales exceeding $2 billion, and Breyanzi's sales are also strong, exceeding $1 billion annually [9][10] Drug Approvals and Pipeline - BMY's recent approval of Opdivo Qvantig for subcutaneous use has enhanced its immuno-oncology portfolio, with strong initial uptake [6] - The company has also launched Cobenfy, a new treatment for schizophrenia, which has generated $105 million in sales year-to-date and is expected to contribute significantly to revenue in the future [10][11] Legacy Portfolio and Challenges - The Legacy Portfolio continues to decline, with a 12% decrease in sales to $5.4 billion, primarily due to generic competition affecting drugs like Revlimid and Pomalyst [12] - BMY anticipates a further decline of approximately 15% to 17% in the Legacy Portfolio by 2025 [13] Strategic Collaborations and Acquisitions - BMY announced the acquisition of Orbital Therapeutics for $1.5 billion, which will add a promising RNA immunotherapy candidate to its pipeline [14][15] - The company has also partnered with BioNTech for the co-development of a bispecific antibody targeting cancer, indicating a focus on innovative treatment approaches [16][17] Valuation and Estimates - BMY's current price/earnings ratio stands at 7.67x, below its historical mean and the large-cap pharma industry's average of 15.57x, suggesting it may be undervalued [18] - The Zacks Consensus Estimate for 2025 EPS has slightly decreased to $6.48 from $6.51 over the past month [20] Investment Outlook - BMY's strong performance in the first nine months of 2025, driven by key drugs, positions it as a relatively safe investment in the biotech sector [22] - The company offers an attractive dividend yield of 5.31%, which may appeal to existing investors [22]

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is facing challenges with its schizophrenia medicine sales, leading to disappointment from investors [1] - The company develops biopharmaceutical products targeting cancer, cardiovascular, autoimmune, and neurological diseases [1] - Comparatively, Johnson & Johnson (J&J) is perceived to be performing better than Bristol-Myers Squibb, causing concern among investors [1] - There is a belief that certain AI stocks may present better investment opportunities with higher upside potential and lower downside risk compared to Bristol-Myers Squibb [1] Company Performance - Jim Cramer expressed doubts about the sales performance of Bristol-Myers Squibb's schizophrenia medication, Cobenfy, indicating it is not selling well [1] - Cramer mentioned that he has not added to his position in Bristol-Myers Squibb due to concerns about its performance relative to competitors like J&J [1] Investment Perspective - While acknowledging the potential of Bristol-Myers Squibb as an investment, there is a suggestion that investors may find more value in certain AI stocks [1]

Alnylam Pharmaceuticals - Alnylam's market worth exceeded many large-cap drugmakers, indicating a challenging position due to high expectations from investors [1] - The company reported quarterly revenues of approximately $1.25 billion, surpassing analyst estimates by nearly $300 million, and boosted its financial forecasts [4] - Amvuttra generated $685 million in sales, exceeding the expected $622 million, indicating growing demand among patients with transthyretin amyloidosis [4] - Despite strong earnings, Alnylam shares fell nearly 7%, attributed to high share prices and elevated investor expectations [3] Biogen - Biogen's latest earnings report showed revenues just above $2.5 billion, narrowly exceeding Wall Street expectations [7] - The company’s aging multiple sclerosis drugs accounted for about 40% of total revenue, while new product launches showed muted performance [8] - Biogen revised its revenue forecast for the year to flat to up 1%, but lowered annual earnings per share estimates to $14.50 to $15 [9] Neurocrine Biosciences - Neurocrine reported a 28% year-over-year increase in net sales, totaling $785 million, but shares fell by 9% following the announcement [11] - The company plans to invest an additional $150 million in expanding sales teams, raising concerns about future margins [12] - Neurocrine received a civil investigative demand from the DOJ regarding Ingrezza, which may have unsettled investors despite a solid quarterly performance [13][14] Bristol Myers Squibb - Bristol Myers' earnings report was positive overall, but the performance of its schizophrenia drug Cobenfy was seen as underwhelming compared to other products [15][16] - Cobenfy sales reached $43 million in the third quarter, with ongoing trials testing its efficacy in treating Alzheimer's-related psychosis [18] - Despite uncertainties surrounding Cobenfy, Bristol Myers' shares rose 7% due to improved financial guidance and quarterly revenue performance [20]

Core Insights - Merck's third-quarter performance exceeded expectations, but challenges with Gardasil and a mixed sales outlook led to a 2.4% decline in stock price [2][10] - Bristol Myers Squibb also reported strong results, raising its full-year sales outlook, while investors are focused on upcoming clinical trial results [2][11] Merck Performance - Merck reported $17.28 billion in sales, a 4% increase, surpassing forecasts of $16.97 billion [7] - Adjusted earnings were $2.58 per share, exceeding expectations of $2.35, with a 64% year-over-year increase [7] - Keytruda, Merck's leading cancer treatment, generated $8.14 billion in sales, a 10% increase, but fell short of the expected $8.2 billion [8] - Sales of Januvia, a diabetes drug, rose 29% to $624 million, significantly exceeding forecasts of $531 million [9] - Merck's sales guidance for the year is now $64.5 billion to $65 billion, slightly narrowed from previous guidance [9][10] New Drug Developments - Winrevair, a new drug for pulmonary arterial hypertension, saw sales of $360 million, a 141% increase, although it missed the $380 million expectation [4][5] - The patient base for Winrevair is growing, with potential market expansion into other forms of pulmonary hypertension [5] Bristol Myers Squibb Performance - Bristol Myers reported adjusted earnings of $1.63 per share and $12.22 billion in sales, both exceeding expectations [11] - Sales growth was driven by its growth portfolio, which increased 18% year-over-year to $6.9 billion [12] - The company raised its full-year sales outlook to $47.5 billion to $48 billion, up from a previous estimate [14]

Industry Overview - The pharmaceutical industry is facing challenges including changing drug pricing policies, tariffs, and pressure to increase U.S. manufacturing [2][3] - Investors are particularly focused on potential "most favored nation" drug pricing deals with the Trump administration, following agreements with major companies [3] Company Earnings Preview - **Merck**: Expected to show topline growth driven by demand for immunotherapy Keytruda and new drug launches, though growth may be offset by sluggish sales of Gardasil in China [4] - **Eli Lilly**: Anticipated to report strong results due to growth in diabetes injection Mounjaro and weight loss drug Zepbound, with potential for an increase in full-year guidance [4] - **Bristol Myers Squibb**: Expected to have modest upside, with significant attention on upcoming phase three trial data for Cobenfy in Alzheimer's disease psychosis, which could represent a multi-billion-dollar opportunity [4] - **Gilead**: Core business improvement expected, particularly in the HIV sector, with focus on the launch of the twice-yearly HIV prevention injection Yeztugo and implications of Trump's pricing policy [4] - **AbbVie**: Anticipated to have a solid quarter with improvements in its aesthetics business and continued strength in Skyrizi and Rinvoq, positioning the company to exceed expectations [4]

Core Viewpoint - Bristol-Myers Squibb Company (BMY) is set to report its third-quarter 2025 results on October 30, with sales and earnings estimates at $11.83 billion and $1.51 per share respectively. Recent earnings estimates for 2025 and 2026 have seen slight declines [1][5]. Financial Performance - The earnings estimate for 2025 has decreased from $6.50 to $6.39 per share over the past 30 days, while the estimate for 2026 has dropped from $6.04 to $6.03 [1]. - BMY has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 22.71%, including a 36.45% beat in the most recent quarter [2][3]. Sales Drivers - The growth portfolio, including drugs like Opdivo, Camzyos, and Reblozyl, is expected to support revenue growth, while generic pressures on legacy drugs like Eliquis and Revlimid may negatively impact overall revenues [5][12]. - Opdivo sales are estimated at $2.43 billion, with strong demand driven by label expansions in new indications [7]. - Reblozyl is experiencing solid growth in both U.S. and international markets, with sales estimates at $583 million [9][10]. - Camzyos and Breyanzi are also expected to show strong sales growth due to increased demand [11][12]. Market Position and Valuation - BMY's shares have underperformed, losing 18.7% year-to-date compared to the industry growth of 11.1% [16][17]. - The current price/earnings ratio for BMY is 7.19x forward earnings, lower than the industry average of 15.59x [18]. Strategic Initiatives - BMY has made strategic acquisitions to enhance its product portfolio, which are beginning to yield results, although the company carries significant debt from these acquisitions [22][23]. - The recent approval of Cobenfy for schizophrenia broadens BMY's portfolio and validates its acquisition of Karuna Therapeutics [22]. - BMY has collaborated with BioNTech for the co-development of a bispecific antibody, sharing development costs and profits equally [24].

Core Viewpoint - Bristol-Myers Squibb Company (NYSE:BMY) is identified as a trending stock with significant deep value potential, trading at a substantial discount to fair value and offering a high dividend yield [1][2] Group 1: Stock Valuation and Performance - BMY is rated as a five-star stock, trading at a 33% discount to its fair value [1] - The stock offers a dividend yield of 5.6% and trades at under eight times earnings estimates for the current year [1] - The company has faced challenges with upcoming patent expirations but has a promising pipeline that may not be fully recognized by the market [1] Group 2: Patent Expiry and Market Competition - BMY has three major franchises facing patent expirations: Revlimid (generic competition starting in 2026), Eliquis (generic entry in 2028/29), and Opdivo (biosimilar competition starting in 2029) [2] - The company is attempting to mitigate the impact of these expirations with new product formulations, such as a subcutaneous version of Opdivo [2] Group 3: Investment Sentiment and Positioning - PGIM Jennison Health Sciences Fund initiated a position in BMY due to perceived undervaluation and positive expectations for its neuropsychiatric drug Cobenfy [2] - The fund later took profits as the stock rallied, but subsequently reduced its position due to concerns over trial designs and disappointing updates on key products [2]

Core Insights - Bristol Myers (BMY) shares have been losing momentum in 2025, with a 4.7% decline in a month compared to a 4.8% gain in the industry, closing at $45.11 on October 2, 2025, below the 50-day simple moving average (SMA) of $45.84 [1][2][7] Stock Performance - The stock reached a 52-week high of $63.33 on March 11 but has since been on a downward trend, hitting a 52-week low of $42.96 on July 31, 2025 [2] - Over the past six months, BMY shares have decreased by 10.5%, while the industry has gained 17% [3] Financial Outlook - The outlook for 2025 has disappointed investors, with a cut in EPS guidance to $6.35-$6.65 from a previous $6.70-$7 due to unfavorable impacts from the BNTX deal [4][16] - Revenues from BMY's legacy portfolio fell by 17% in the first half of 2025, with expectations of a decline of approximately 15% to 17% for the full year [8][9] Drug Portfolio Performance - BMY's growth portfolio includes drugs like Opdivo and Reblozyl, which have shown strong performance, with Opdivo sales expected to grow in the mid to high-single-digit range [10][11] - Reblozyl has generated over $1 billion in global sales year-to-date, while Breyanzi sales increased by 134% to $607 million in the first half [12] Debt and Valuation - As of June 30, 2025, BMY had cash and equivalents of $12.6 billion and long-term debt of $44.5 billion, raising concerns about its high debt ratio [14] - BMY is trading at a price/earnings ratio of 7.12X forward earnings, lower than its historical mean of 8.45X and the large-cap pharma industry's 15.70X [17] Market Sentiment - The recent slip below the 50-day SMA indicates bearish sentiment, although BMY is considered a safe haven for long-term investors in the biotech sector [21] - The company's attractive dividend yield of 5.64% is a reason for existing investors to remain invested [21]